Literature DB >> 25328449

Treatment options in Invasive Aspergillosis.

Anil A Panackal, John E Bennett, Peter R Williamson.   

Abstract

Entities:  

Keywords:  antifungals; immunotherapy; invasive aspergillosis; neutropenia

Year:  2014        PMID： 25328449      PMCID： PMC4200583          DOI： 10.1007/s40506-014-0016-2

Source DB:  PubMed          Journal:  Curr Treat Options Infect Dis        ISSN： 1523-3820


× No keyword cloud information.
  83 in total

1.  Cytomegalovirus infections in cancer patients receiving granulocyte transfusions.

Authors:  W Garrett Nichols; Thomas Price; Michael Boeckh
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

4.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

5.  The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation.

Authors:  Amar Safdar; Gilhen Rodriguez; Norio Ohmagari; Dimitrios P Kontoyiannis; Kenneth V Rolston; Issam I Raad; Richard E Champlin
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

6.  Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Georgia Georgescu; Anupam Pande
Journal:  Acta Haematol       Date:  2012-10-02       Impact factor: 2.195

7.  Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.

Authors:  A C Leenders; S Daenen; R L Jansen; W C Hop; B Lowenberg; P W Wijermans; J Cornelissen; R Herbrecht; H van der Lelie; H C Hoogsteden; H A Verbrugh; S de Marie
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

8.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Authors:  Catherine Cordonnier; Cécile Pautas; Sébastien Maury; Anne Vekhoff; Hassan Farhat; Felipe Suarez; Nathalie Dhédin; Francoise Isnard; Lionel Ades; Frédérique Kuhnowski; Françoise Foulet; Mathieu Kuentz; Patrick Maison; Stéphane Bretagne; Michaël Schwarzinger
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.

Authors:  Anil A Panackal; Emilio Parisini; Michael Proschan
Journal:  Int J Infect Dis       Date:  2014-09-18       Impact factor: 3.623
View more
  5 in total

1.  Intracranial Aspergillosis in an Immunocompetent Young Woman.

Authors:  Prasan Kumar Panda; Sunil Kumar Mavidi; Naveet Wig; Ajay Garg; Aasma Nalwa; M C Sharma
Journal:  Mycopathologia       Date:  2017-01-04       Impact factor: 2.574

2.  Novel Hit Compounds as Putative Antifungals: The Case of Aspergillus fumigatus.

Authors:  Eftichia Kritsi; Minos-Timotheos Matsoukas; Constantinos Potamitis; Anastasia Detsi; Marija Ivanov; Marina Sokovic; Panagiotis Zoumpoulakis
Journal:  Molecules       Date:  2019-10-25       Impact factor: 4.411

3.  Comparative Host-Pathogen Interaction Analyses of SARS-CoV2 and Aspergillus fumigatus, and Pathogenesis of COVID-19-Associated Aspergillosis.

Authors:  Abdul Arif Khan; Fozia Farooq; Sudhir K Jain; Patrycja Golinska; Mahendra Rai
Journal:  Microb Ecol       Date:  2021-11-04       Impact factor: 4.192

Review 4.  Aspergillus Endophthalmitis: Epidemiology, Pathobiology, and Current Treatments.

Authors:  Alisha Khambati; Robert Emery Wright; Susmita Das; Shirisha Pasula; Alejandro Sepulveda; Francis Hernandez; Mamta Kanwar; Pranatharthi Chandrasekar; Ashok Kumar
Journal:  J Fungi (Basel)       Date:  2022-06-22

5.  Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B.

Authors:  Robert J van de Peppel; Alexander Schauwvlieghe; Ruth Van Daele; Isabel Spriet; Jan W Van't Wout; Roger J Brüggemann; Bart J A Rijnders; Bart J C Hendriks; Mark G J de Boer
Journal:  Med Mycol       Date:  2020-10-01       Impact factor: 4.076
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.